News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Welch Allyn restructuring to cut jobs by 10% over three years. Neurovision v. NuVasive update. CMS opens coverage analysis on PET for solid tumors. More news briefs.
You may also be interested in...
Reimbursement In Brief
CMS issues proposed decision memo for PET for solid tumors and sends letter to Smith & Nephew clarifying G codes for negative pressure wound therapies. More reimbursement news.
Blues’ TEC Delivers Mostly Negative Assessments For Three Technologies
The Blue Cross Blue Shield Technology Evaluation Center considered balloon ostial dilation for the treatment for chronic rhinosinusitis; multianalyte testing for evaluation of adnexal masses; and nucleic acid sequencing-based testing of maternal plasma for fetal aneuploidy.
CMS Urged To Lift All Evidence-Development Restrictions On PET For Solid Tumors
Move to lift coverage-with-evidence-development restrictions is widely supported by industry, medical specialty societies and clinicians.